NCT05350046 is a NA clinical trial of Ear-worn prototype devices in Hearing Loss, sponsored by 57GGardner.

Who is sponsoring NCT05350046?

NCT05350046 is sponsored by 57GGardner.

What drugs are being tested in NCT05350046?

Interventions in NCT05350046: Ear-worn prototype devices.

What condition does NCT05350046 study?

NCT05350046 studies Hearing Loss, Well Aging.

Is NCT05350046 still recruiting?

NCT05350046 is currently completed. Last updated 4 December 2023.

Last reviewed 2023-12-04 · How we verify

NCT05350046

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of Physical Activity Features for Ear-worn Devices

Completed NA Last updated 4 December 2023

What this trial tests

NA trial testing Ear-worn prototype devices in Hearing Loss in 30 participants. Completed in 24 April 2023.

Timeline

11 July 2022

Primary endpoint
24 April 2023

24 April 2023

Quick facts

Lead sponsor	57GGardner
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	30
Start date	11 July 2022
Primary completion	24 April 2023
Estimated completion	24 April 2023
Sites	1 location across United States

Drugs / interventions tested

Ear-worn prototype devices

Conditions studied

Hearing Loss — all drugs for Hearing Loss →
Well Aging — all drugs for Well Aging →

Sponsor

57GGardner

Who can join

Adults 40 to 85, any sex, with Hearing Loss or Well Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study incorporates data collection to aid in development of software features related to physical activity for users of ear-worn devices.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hearing Loss

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III · Phase 1 · recruiting
NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05350046 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 57GGardner
Last refreshed: 4 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05350046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing